Knight Therapeutics
Market Cap
CA$1.0b
Last Updated
2019/10/17 00:29 UTC
Data Sources
Company Financials +
Executive Summary
Knight Therapeutics Inc. operates as a specialty pharmaceutical company in Canada and internationally.
Snowflake
Fundamentals
Flawless balance sheet with reasonable growth potential.
Similar Companies
Share Price & News
How has Knight Therapeutics's share price performed over time and what events caused price changes?
Latest Share Price and Events
Market Performance
7 Day Return
1.8%
GUD
0.8%
CA Pharmaceuticals
0.2%
CA Market
1 Year Return
-7.3%
GUD
-57.9%
CA Pharmaceuticals
1.2%
CA Market
Return vs Industry: GUD exceeded the Canadian Pharmaceuticals industry which returned -57.9% over the past year.
Return vs Market: GUD underperformed the Canadian Market which returned 1.2% over the past year.
Shareholder returns
| GUD | Industry | Market | |
|---|---|---|---|
| 7 Day | 1.8% | 0.8% | 0.2% |
| 30 Day | 0.3% | -23.6% | -2.5% |
| 90 Day | -0.3% | -34.0% | -1.5% |
| 1 Year | -7.3%-7.3% | -57.9%-57.9% | 4.7%1.2% |
| 3 Year | -15.7%-15.7% | 77.3%76.0% | 14.0%3.8% |
| 5 Year | 30.3%30.3% | 280.0%280.0% | 26.4%8.1% |
Price Volatility Vs. Market
How volatile is Knight Therapeutics's share price compared to the market and industry in the last 5 years?
Simply Wall St News
6 days ago | Simply Wall St
What Type Of Shareholder Owns Knight Therapeutics Inc.'s (TSE:GUD)?1 month ago | Simply Wall St
Does Knight Therapeutics Inc. (TSE:GUD) Have A Particularly Volatile Share Price?2 months ago | Simply Wall St
Have Insiders Been Buying Knight Therapeutics Inc. (TSE:GUD) Shares?Valuation
Is Knight Therapeutics undervalued compared to its fair value and its price relative to the market?
28.84x
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Undervalued: GUD (CA$7.53) is trading above our estimate of fair value (CA$2)
Significantly Undervalued: GUD is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: GUD is poor value based on its PE Ratio (28.8x) compared to the Pharmaceuticals industry average (11.1x).
PE vs Market: GUD is poor value based on its PE Ratio (28.8x) compared to the Canadian market (13.7x).
Price to Earnings Growth Ratio
Low PEG Ratio: GUD is poor value based on its PEG Ratio (1.6x)
Price to Book Ratio
PB vs Industry: GUD is good value based on its PB Ratio (1x) compared to the CA Pharmaceuticals industry average (1.9x).
Next Steps
Future Growth
How is Knight Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 7 analysts?
18.4%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: GUD's forecast earnings growth (18.4% per year) is above the savings rate (1.9%).
Earnings vs Market: GUD's earnings (18.4% per year) are forecast to grow faster than the Canadian market (13.3% per year).
High Growth Earnings: GUD's earnings are forecast to grow, but not significantly.
Revenue vs Market: GUD's revenue (42.2% per year) is forecast to grow faster than the Canadian market (5.7% per year).
High Growth Revenue: GUD's revenue (42.2% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
High Future ROE: GUD's Return on Equity is forecast to be low in 3 years time (4%).
Next Steps
Past Performance
How has Knight Therapeutics performed over the past 5 years?
-50.1%
Historical annual earnings growth
Earnings and Revenue History
Past Earnings Growth Analysis
Earnings Trend: GUD's earnings have declined by -50.1% per year over the past 5 years.
Accelerating Growth: GUD's earnings growth over the past year (72.1%) exceeds its 5-year average (-50.1% per year).
Earnings vs Industry: GUD earnings growth over the past year (72.1%) exceeded the Pharmaceuticals industry 15.6%.
Return on Equity
High ROE: GUD's Return on Equity (3.6%) is considered low.
Return on Assets
ROA vs Industry: GUD's Return on Assets is below or equal to the Pharmaceuticals industry average last year.
Return on Capital Employed
ROCE Improving: GUD is currently unprofitable, so its Return on Capital Employed is negative.
Next Steps
Financial Health
How is Knight Therapeutics's financial position?
Financial Position Analysis
Short Term Liabilities: GUD's short term assets (CA$626.8M) exceeds its short term liabilities (CA$19.9M)
Long Term Liabilities: GUD's short term assets (626.8M) exceeds its long term liabilities (6.3M)
Debt to Equity History and Analysis
Debt Level: GUD is debt free.
Reducing Debt: GUD has not had any debt for past 5 years.
Debt Coverage: GUD has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: GUD has no debt, therefore coverage of interest payments is not a concern.
Balance Sheet
Inventory Level: GUD has a low level of unsold assets or inventory.
Debt Coverage by Assets: Insufficient data to determine if GUD's debt is covered by short term assets.
Next Steps
Dividend
What is Knight Therapeutics's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Current dividend yield vs market & industry
Stability and Growth of Payments
Notable Dividend: Unable to evaluate GUD's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate GUD's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stable Dividend: Insufficient data to determine if GUD's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if GUD's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of GUD's dividend in 3 years as they are not forecast to pay a notable one for the Canadian market.
Next Steps
Management
What is the CEO of Knight Therapeutics's salary, the management and board of directors tenure and is there insider trading?
2.2yrs
Average board tenure
CEO
Jonathan Goodman (50yo)
0yrs
Tenure
CA$994,692
Compensation
Mr. Jonathan Ross Goodman, BA, LLB, MBA founded Knight Therapeutics Inc. in February 2014 and serves as its Chief Executive Officer. Mr. Goodman served as President of Knight Therapeutics Inc. until August ...
CEO Compensation Analysis
Compensation vs. Market: Jonathan's total compensation ($USD754.14K) is about average for companies of similar size in the Canadian market ($USD1.55M).
Compensation vs Earnings: Jonathan's compensation has been consistent with company performance over the past year.
Board Age and Tenure
2.2yrs
Average Tenure
54yo
Average Age
Experienced Board: GUD's board of directors are not considered experienced ( 2.2 years average tenure), which suggests a new board.
Insider Trading
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
| Entity | Individual |
| Role | Member of the Board of Directors Independent Director |
| Shares | 20,000 |
| Max Price | CA$7.52 |
| Entity | Individual |
| Role | Chief Executive Officer Founder |
| Shares | 3,200 |
| Max Price | CA$7.63 |
| Entity | Individual |
| Role | Chief Executive Officer Founder |
| Shares | 12,000 |
| Max Price | CA$7.59 |
| Entity | Individual |
| Role | Chief Executive Officer Founder |
| Shares | 10,000 |
| Max Price | CA$7.39 |
| Entity | Individual |
| Role | Chief Executive Officer Founder |
| Shares | 17,800 |
| Max Price | CA$7.37 |
| Entity | Individual |
| Role | Chief Executive Officer Founder |
| Shares | 9,000 |
| Max Price | CA$7.42 |
| Entity | Individual |
| Role | Chief Executive Officer Founder |
| Shares | 7,200 |
| Max Price | CA$7.38 |
| Entity | Individual |
| Role | Chief Executive Officer Founder |
| Shares | 23,400 |
| Max Price | CA$7.33 |
| Entity | Individual |
| Role | Chief Executive Officer Founder |
| Shares | 99,000 |
| Max Price | CA$7.60 |
| Entity | Individual |
| Role | Member of the Board of Directors President |
| Shares | 12,987 |
| Max Price | CA$7.70 |
Ownership Breakdown
Management Team
Samira Sakhia (50yo)
President
- Tenure: 3.2yrs
- Compensation: CA$786.56k
Jonathan Goodman (50yo)
Founder
- Tenure: 0yrs
- Compensation: CA$994.69k
Amal Khouri
Vice President of Business Development
- Tenure: 5.2yrs
- Compensation: CA$614.81k
Jody Engel
Director of Business Development
- Tenure: 0yrs
- Compensation: CA$295.72k
Michel Loustric
President of Knight Barbados
- Tenure: 0yrs
- Compensation: CA$251.51k
Arvind Utchanah
Director of Finance
- Tenure: 0yrs
- Compensation: CA$267.78k
Board Members
Nancy Harrison (54yo)
Independent Director
- Tenure: 1.2yrs
- Compensation: CA$55.96k
Jim Gale (69yo)
Independent Chairman
- Tenure: 0yrs
- Compensation: CA$87.03k
Samira Sakhia (50yo)
President
- Tenure: 3.2yrs
- Compensation: CA$786.56k
Robert Lande (56yo)
Independent Director
- Tenure: 5.8yrs
- Compensation: CA$96.24k
Jonathan Goodman (50yo)
Founder
- Tenure: 0yrs
- Compensation: CA$994.69k
Mike Tremblay
Independent Director
- Tenure: 0.4yrs
Sylvie Tendler
Independent Director
- Tenure: 5.2yrs
- Compensation: CA$82.65k
Kevin Cameron
Director
- Tenure: 0.4yrs
Company Information
Knight Therapeutics Inc.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: Knight Therapeutics Inc.
- Ticker: GUD
- Exchange: TSX
- Founded:
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: CA$1.024b
- Shares outstanding: 135.96m
- Website: https://www.gud-knight.com
Number of Employees
Location
- Knight Therapeutics Inc.
- 3400 De Maisonneuve Boulevard West
- Suite 1055
- Montreal
- Quebec
- H3Z 3B8
- Canada
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| GUD | TSX (The Toronto Stock Exchange) | Yes | Common Shares | CA | CAD | Mar 2014 |
| KHTR.F | OTCPK (Pink Sheets LLC) | Yes | Common Shares | US | USD | Mar 2014 |
| 04K | DB (Deutsche Boerse AG) | Yes | Common Shares | DE | EUR | Mar 2014 |
Biography
Knight Therapeutics Inc. operates as a specialty pharmaceutical company in Canada and internationally. The company is involved in developing, acquiring, in-licensing, out-licensing, marketing, and distribu ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2019/10/17 00:29 |
| End of Day Share Price | 2019/10/16 00:00 |
| Earnings | 2019/06/30 |
| Annual Earnings | 2018/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.